Last updated on: 8/12/2016 | Author: ProCon.org

Brenda Porter, MD, PhD Biography

Title:
Associate Professor of Neurology at Stanford University Medical Center
Position:
Pro to the question "Should Marijuana Be a Medical Option?"
Reasoning:

“The average number of anti-epileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child’s seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported 25-60% seizure reduction. Other beneficial effects included increased drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for children with treatment-resistant epilepsy.”

“Report of a Parent Survey of Cannabidiol-Enriched Cannabis Use in Pediatric Treatment-Resistant Epilepsy,” Epilepsy & Behavior, Dec. 29, 2013

Involvement and Affiliations:
  • Associate Professor of Neurology, Stanford University Medical Center
  • Member, Bio-X
  • Member, Child Health Research Institute
  • Member, Stanford Neurosciences Institute
  • Education:
  • MD, Washington University School of Medicine, 1995
  • PhD, Neurobiology, Washington University School of Medicine, 1995
  • AB, Biochemistry, Washington University, 1987
  • Other:
  • Residency, Hospital of the University of Pennsylvania, 2000
  • Residency, St. Louis Children’s Hospital, 1997
  • Internship, St. Louis Children’s Hospital, 1996
  • Board Certification, Clinical Neurophysiology, American Board of Psychiatry and Neurology, 2003
  • Board Certification, Child Neurology, American Board of Psychiatry and Neurology, 2002
  • Fellowship, The Children’s Hospital of Philadelphia, 2002